Researchers to test TRV027, a potential COVID-19 treatment in UK

Researchers at Imperial College London are investigating TRV027 in 60-patient pilot study. TRV027 is reported to block angiotensin II activity and mimic angiotensin (1-7) activity thus targets the cell pathways thought to be major drivers of severe illness in COVID-19.